Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ESMO update: upper gastrointestinal cancer
This study led to the approval of trastuzumab–deruxtecan as second-line therapy in patients with Her2-positive gastric and gastroesophageal junction tumors who have experienced disease progression after first-line trastuzumab-containing therapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 5, 2023 Category: Cancer & Oncology Source Type: research

ESMO 2022 personal non-small lung cancer (NSCLC) highlights
SummaryIn this article, we summarize our personal non-small cell lung cancer (NSCLC) highlights from the ESMO 2022 meeting, covering developments in early- and advanced-stage NSCLC. In early-stage disease, many studies underlined possibilities of neoadjuvant and adjuvant treatment, including neoadjuvant immunotherapy combination strategies (INCREASE trial) or adjuvant targeted therapy with osimertinib in epidermal growth factor receptor (EGFR)-mutated NSCLC (updated results of ADAURA), both promoting interesting concepts to further improve outcomes in early-stage NSCLC. In late-stage disease, results from CodeBreak200, the...
Source: Memo - Magazine of European Medical Oncology - May 5, 2023 Category: Cancer & Oncology Source Type: research

Immunotherapy for metastatic melanoma —from little benefit to first-line treatment
SummaryAt the turn of the past century, unresectable metastatic melanoma was primarily treated with different chemotherapeutic agents, such as dacarbazine, with only poor efficacy. Immunotherapeutic agents, such as interleukin ‑2 or adjuvant interferon alpha, were used with modest results but frequent side effects. In the last 10 years, modern immunotherapy using checkpoint inhibition has dramatically changed the treatment landscape of metastatic melanoma and is now considered the first-line treatment for stage IV mel anoma. Consequently, median overall survival has increased from 9.1 months with dacarbazine to up to ...
Source: Memo - Magazine of European Medical Oncology - May 3, 2023 Category: Cancer & Oncology Source Type: research

Lessons learned in adjuvant colorectal cancer
SummaryColorectal cancer (CRC) is one of the most frequent malignancies. While adjuvant fluoropyrimidine-based chemotherapy has been established as standard of care for patients with stage III disease, its value and role are still uncertain for stage II disease. This review discusses the usefulness of adjuvant therapy in both stages and highlights the use of liquid biopsy via circulating tumor DNA (ctDNA) for the assessment of minimal residual disease which will shape the therapy d ecision for adjuvant treatment in future. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 28, 2023 Category: Cancer & Oncology Source Type: research

Molecular pathology of colorectal cancer
SummaryColorectal cancer (CRC) is a molecularly heterogeneous disease arising from gradual accumulation of genetic and epigenetic changes. In the last decade, great efforts have been made to classify CRC according to molecular features. This has led to several proposals of molecular subtyping. Recently, consensus molecular subtypes (CMS) have been proposed based on the integration of previously existing categorizations and additional comprehensive molecular studies. Microsatellite instability (MSI) is a highly specific molecular feature in CRC with a therapeutic impact, for example for immunotherapy. MSI is recognized ...
Source: Memo - Magazine of European Medical Oncology - April 27, 2023 Category: Cancer & Oncology Source Type: research

How the long-term follow-up is organized in young adult survivors of childhood cancer
SummaryThe survival after childhood cancer has improved substantially, therefore the population of childhood cancer survivors is increasing. This growing population of childhood cancer survivors, however, is at risk of a spectrum of adverse health outcomes. Unfortunately, until now, there was a lack of comprehensive follow-up recommendations.The purpuse of this article is to provide information on recently developed harmonized evidence-based guidelines and the structure to provide complex long term follow up for childhood cancer survivors. We pointed out the need for a multidisciplinary pediatric and adult specialist tea...
Source: Memo - Magazine of European Medical Oncology - April 27, 2023 Category: Cancer & Oncology Source Type: research

A CONGRESS DIGEST ON NEUROENDOCRINE TUMORS. Report from the North American Neuroendocrine Tumor Society (NANETS) Annual Medical Symposium, 27th – 29th October 2022, Washington
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 26, 2023 Category: Cancer & Oncology Source Type: research

A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), October 15th – 19th, 2022, Barcelona
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 26, 2023 Category: Cancer & Oncology Source Type: research